

CITATION REPORT

List of articles citing

Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials

DOI: 10.1111/j.1365-2036.2006.02932.x

Alimentary Pharmacology and Therapeutics, 2006, 23, 1535-4

Source: <https://exaly.com/paper-pdf/40425878/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
320	Percutaneous radiofrequency thermal ablation for hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 1495-501	6.1	13
319	Expanding HCC criteria for liver transplant: the urgent need for prospective, robust data. 2006 , 12, 1741-3		14
318	Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. 2006 , 12, 1747-54		15
317	Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. 2006 , 26, 248-53		26
316	Can response to TACE predict survival after liver transplantation in patients with hepatocellular carcinoma?. 2007 , 4, 540-1		
315	Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. 2007 , 12, 1425-32		43
314	Emerging approaches in hepatocellular carcinoma. 2007 , 41, 839-54		15
313	Interventional radiology as a fine art. 2007 , 46, 362-4		2
312	Current management of liver cancer. 2007 , 5, 444-446		4
311	Management of hepatocellular carcinoma. 2007 , 11, 305-21		17
310	[Updated guide for diagnosis, staging and treatment of hepatocellular carcinoma]. 2007 , 128, 741-8		3
309	From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. 2007 , 72 Suppl 1, 30-44		155
308	Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. 2007 ,		3
307	Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. 2007 , 46, 446-55		62
306	Proton beam therapy for aged patients with hepatocellular carcinoma. 2007 , 69, 805-12		50
305	[Hepatic transplantation for hepatocellular carcinoma: state of the art]. 2007 , 144, 105-10		1
304	[Regional therapy of liver tumors]. 2007 , 48, 40-5		3

303	Lokal-ablative Therapie. 2007 , 2, 27-33		1
302	Standards und neue Aspekte der Diagnostik und Therapie des hepatozellulären Karzinoms. 2008 , 1, 109-119		
301	Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. 2008 , 2, 116-23		47
300	Molecular targeted therapies in hepatocellular carcinoma. 2008 , 48, 1312-27		801
299	Laparoscopic radiofrequency ablation of unresectable hepatocellular carcinoma: long-term follow-up. 2008 , 10, 315-20		22
298	Usefulness of surveillance programmes for early diagnosis of hepatocellular carcinoma in clinical practice. 2008 , 28, 682-9		25
297	Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 1269-77	6.1	51
296	Sorafenib in advanced hepatocellular carcinoma. 2008 , 359, 378-90		9089
295	Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. 2008 , 1, 18		45
294	Pivotal role of mTOR signaling in hepatocellular carcinoma. 2008 , 135, 1972-83, 1983.e1-11		563
293	Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. 2008 , 40, 684-9		25
292	Novel advancements in the management of hepatocellular carcinoma in 2008. 2008 , 48 Suppl 1, S20-37		635
291	Pharmacotherapy of chronic viral hepatitis and hepatocellular carcinoma. 2008 , 9, 2233-45		
290	Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. 2008 , 24, 3559-69		25
289	Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. 2008 , 2, 761-84		11
288	Comparison of ultrasound strain images with multi-modality imaging techniques in liver RF ablation assessment: Initial ex vivo and clinical results. 2008 ,		2
287	Design and endpoints of clinical trials in hepatocellular carcinoma. 2008 , 100, 698-711		1360
286	Sorafenib in hepatocellular carcinoma: separating the hype from the hope. 2008 , 26, 5845-8		26

- 285 Embolotherapy in the management of hepatocellular carcinoma. **2008**, 25, 234-41 3
- 284 Hepatocarcinoma in viral and metabolic liver disease. **2008**, 46, 370-5 8
- 283 Targeting vessels to treat hepatocellular carcinoma. **2008**, 114, 467-77 6
- 282 Re: Effect of Enteral Nutrition and Symbiotics on Bacterial Infection Rates After Pylorus-Preserving Pancreatoduodenectomy. **2008**, 247, 561
- 281 Should We Disconnect Perforated and Nonperforated Appendicitis in Children?. **2008**, 247, 554
- 280 Nonperforated versus perforating appendicitis. **2008**, 247, 554; author reply 554-5
- 279 Surgery or ablation for hepatocellular carcinoma?. **2008**, 247, 557-8 12
- 278 Re: effect of enteral nutrition and symbiotics on bacterial infection rates after pylorus-preserving pancreatoduodenectomy. **2008**, 247, 560-1; author reply 561 2
- 277 Re: Laparoscopic Versus Open Appendectomy in Children: A Meta-analysis. **2008**, 247, 555-556
- 276 HBV X protein: elucidating a role in oncogenesis. **2008**, 3, 455-470
- 275 Resolving Appendicitis Is Common: Further Evidence. **2008**, 247, 553
- 274 The price of doubt is esophageal adenocarcinoma. **2008**, 247, 558-9; author reply 559-60 3
- 273 Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. **2008**, 20, 444-53 51
- 272 Re: mortality after groin hernia surgery. **2008**, 247, 560; author reply 560
- 271 The Price of Doubt is Esophageal Adenocarcinoma. **2008**, 247, 559-560
- 270 Nonperforated Versus Perforating Appendicitis. **2008**, 247, 554-555
- 269 Re: Laparoscopic Versus Open Appendectomy in Children: A Meta-analysis. **2008**, 247, 555; author reply 555-6
- 268 Should we disconnect perforated and nonperforated appendicitis in children?. **2008**, 247, 553-4; author reply 554

267	Re: Mortality After Groin Hernia Surgery. 2008 , 247, 560	1
266	Resolving appendicitis is common: further evidence. 2008 , 247, 553; author reply 553	16
265	Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei: need to establish a multi-institutional registry. 2008 , 247, 556-7	1
264	Hepatocellular carcinoma: management of an increasingly common problem. 2008 , 21, 266-80	128
263	Immunotherapy of HCC. 2008 , 3, 31-9	47
262	Ultrasound-based elastography: a novel approach to assess radio frequency ablation of liver masses performed with expandable ablation probes: a feasibility study. 2008 , 27, 935-46	40
261	[Local therapy for hepatocellular carcinoma as a bridge to liver transplantation]. 2009 , 36, 487-92	
260	Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report. 2009 , 2, 9133	3
259	Identification of genes conferring resistance to 5-fluorouracil. 2009 , 106, 12938-43	128
258	Changing the clinical picture of challenging tumors: tales becoming reality?. 2009 , 5, 785-802	1
257	[Hepatic resection for hepatocellular carcinoma--results and analysis of the current literature]. 2009 , 134, 127-35	16
256	Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. 2009 , 9, 31	106
255	Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis. 2009 , 27, 2615-21	92
254	Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. 2009 , 49, 453-9	328
253	Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor-suppression in rat hepatocellular carcinoma. 2009 , 49, 1944-53	74
252	A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. 2009 , 135, 1437-45	99
251	Transarterielle Chemoembolisation bei hepatozellulärem Karzinom [neue Entwicklungen]. 2009 , 4, 330-339	1
250	[Diagnosis and treatment of hepatocellular carcinoma]. 2009 , 132, 272-87	37

249	Clinical research in hepatocellular carcinoma: study design and endpoints. 2009 , 50, 850-3	3
248	Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. 2009 , 51, 890-7	299
247	Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. 2009 , 3, 353-67	221
246	Sorafenib for the treatment of hepatocellular carcinoma across geographic regions. 2009 , 2, 129-36	8
245	Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. 2009 , 44, 1477-86	25
244	Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. 2009 , 10, 25-34	4161
243	Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. 2009 , 9, 739-45	96
242	Current management of hepatocellular carcinoma. 2009 , 93, 885-900, viii	45
241	Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. 2010 , 22, 391-8	56
240	Sorafenib in hepatocellular carcinoma. 2010 , 71, 451-6	13
239	[New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology]. 2010 , 151, 1763-8	2
238	A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. 2010 , 65, 373-82	44
237	Capecitabine plus cisplatin treatment in patients with advanced hepatocellular carcinoma. 2010 , 9, 718-723	
236	Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?. 2010 , 41, 217-20	17
235	Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. 2010 , 4, 439-74	825
234	Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. 2010 , 116, 4590-6	129
233	Is it time to reconsider the BCLC/AASLD therapeutic flow-chart?. 2010 , 102, 868-76	23
232	Inherited hepatocellular carcinoma. 2010 , 24, 725-34	17

231	Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. 2010 , 78, 172-9		84
230	Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. 2010 , 64, 1034-41		59
229	Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 32, 543-50	6.1	28
228	Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. 2010 , 15, 85-92		139
227	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. 2010 , 56, e1-48		160
226	Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?. 2010 , 15 Suppl 4, 42-52		121
225	Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. 2010 , 31, 1643-8		37
224	Current strategy for staging and treatment: the BCLC update and future prospects. 2010 , 30, 61-74		770
223	Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents. 2010 , 9, 127		20
222	Future perspectives in hepatocellular carcinoma. 2010 , 42 Suppl 3, S302-9		55
221	[Treatment of advanced hepatocellular carcinoma]. 2010 , 33, 461-8		2
220	Radiofrequency ablation is justified for elderly patients with hepatocellular carcinoma. 2010 , 40, 954-5		1
219	Novel inhibitors in development for hepatocellular carcinoma. 2010 , 19, 615-29		24
218	Hepatocellular carcinoma: locoregional and targeted therapies. 2011 , 40, 599-610		6
217	Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. 2011 , 9, 79-86		124
216	Hepatocellular Carcinoma:. 2011 ,		3
215	ZL11n is a novel nitric oxide-releasing derivative of farnesylthiosalicylic acid that induces apoptosis in human hepatoma HepG2 cells via MAPK/mitochondrial pathways. 2011 , 409, 752-7		8
214	Risk factors for long-term prognosis in hepatocellular carcinoma after radiofrequency ablation therapy: the clinical implication of aspartate aminotransferase-platelet ratio index. 2011 , 23, 528-36		48

213	Predictors of surgical intervention for hepatocellular carcinoma: race, socioeconomic status, and hospital type. 2011 , 146, 778-84	62
212	Electro-coagulation for liver metastases. 2011 ,	1
211	Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. 2011 , 31, 1144-9	50
210	Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography. 2011 , 11, 28	19
209	Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists. 2011 , 56, 569-77	24
208	Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. 2011 , 11, 67	29
207	p28GANK overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1 pathways. 2011 , 53, 181-92	111
206	Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. 2011 , 117, 125-33	34
205	The Golden State of healthcare reform: ethnoeconomic origins of outcome imbalance. 2011 , 146, 784-5	
204	An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. 2011 , 7, 463-75	83
203	Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis. 2011 , 83, 275-82	13
202	Targeted-therapy and imaging response: a new paradigm for clinical evaluation?. 2011 , 6, 259-65	18
201	Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. 2011 , 11, 1807-16	19
200	Herbal medicine and hepatocellular carcinoma: applications and challenges. 2011 , 2011, 541209	38
199	Independent factors and predictive score for extrahepatic metastasis of hepatocellular carcinoma following curative hepatectomy. 2012 , 17, 963-9	27
198	Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. 2012 , 17, 1063-72	80
197	Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. 2012 , 12, 1283-8	7
196	Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. 2012 , 6, 173-85	51

195	Microwave coagulation for liver metastases. 2012,	1
194	Long-term survival of patients with hepatocellular carcinoma with pulmonary and adrenal metastasis: A case report. 2012, 3, 699-702	5
193	Neuroepithelial transforming protein 1 short interfering RNA-mediated gene silencing with microbubble and ultrasound exposure inhibits the proliferation of hepatic carcinoma cells in vitro. 2012, 31, 853-61	13
192	Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases. 2012, CD009498	9
191	Hepatocarcinoma. 2012, 11, 693-703	
190	A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma. 2012, 30, 2015-25	23
189	Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma. 2012, 11, 185-90	15
188	A traditional Chinese herbal medicine compound preparation versus interventional therapy after resection of small hepatocellular carcinoma: 22-year follow-up. 2012, 32, 156-63	8
187	Interventional radiologic treatment of hepatocellular carcinoma-a cost analysis from the payer perspective. 2012, 23, 306-14	36
186	Impact of restricting access to high-cost medications for hepatocellular carcinoma. 2012, 12, 465-73	6
185	The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. 2012, 32, 1053-63	83
184	EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. 2012, 56, 908-43	4465
183	EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. 2012, 48, 599-641	356
182	Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. 2012, 12, 64	34
181	Hepatocellular Carcinoma. 2012, 141-157	
180	Imaging Tumor Response to Therapy. 2012,	2
179	Survival after locoregional treatments for hepatocellular carcinoma: a cohort study in real-world patients. 2012, 2012, 564706	19
178	Comparison of epirubicin-iodized oil suspension and emulsion for transcatheter arterial chemoembolization in VX2 tumor. 2012, 2012, 961986	8

177	Systemic Management of Advanced Hepatocellular Carcinoma Patients: The Role of Multi-Targeted Anti-Angiogenic Inhibitors. 2012 ,	
176	Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report. 2012 , 6, 38	11
175	International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18. 2012 , 55, 1122-9	33
174	Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. 2012 , 30, 1150-7	8
173	Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. 2012 , 30, 1540-7	14
172	Synergistic effects of the combination of Eonone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells. 2012 , 30, 1449-59	13
171	Preventive effects of jiedu granules combined with cinobufacini injection versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: a case-control trial. 2012 , 18, 339-44	21
170	The effect of HS-111, a novel thiazolamine derivative, on apoptosis and angiogenesis of hepatocellular carcinoma cells. 2012 , 35, 747-54	2
169	Tumor response and apoptosis of N1-S1 rodent hepatomas in response to intra-arterial and intravenous benzamide riboside. 2012 , 35, 645-52	4
168	First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. 2012 , 66, 675-83	90
167	The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. 2012 , 8, 164-71	23
166	A rare occurrence of hepatocellular carcinoma metastasis to the mandible: report of a case and review of the literature. 2012 , 70, 1219-23	10
165	High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma. 2013 , 11, 41	35
164	Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). 2013 , 33, 327-37	52
163	Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. 2013 , 24, 307-15	57
162	Serglycin (SRGN) overexpression predicts poor prognosis in hepatocellular carcinoma patients. 2013 , 30, 707	36
161	Evaluation of MAGE-D4 expression in hepatocellular carcinoma in Japanese patients. 2013 , 108, 557-62	19
160	Sorafenib prolongs liver regeneration after hepatic resection in rats. 2013 , 184, 847-54	6

159	Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. 2013 , 11, 1636-45.e1-3		61
158	Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 62-73	6.1	53
157	Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 355-63	6.1	68
156	Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C. 2013 , 45, 510-5		17
155	Systemic therapies in hepatocellular carcinoma: present and future. 2013 , 9, 1533-48		38
154	Microwave coagulation for liver metastases. 2013 , CD010163		11
153	Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases. 2013 , CD009498		16
152	Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?. 2013 , 2, 93-107		30
151	Surgical strategy for liver cancers in the era of effective chemotherapy. 2013 , 2, 47-54		19
150	The promise of clinical interventions for hepatocellular carcinoma from the west to mainland China. 2013 , 11, 503-22		4
149	Comparison of the antitumor efficacy of transcatheter arterial chemoembolization with a miriplatin-iodized oil suspension and a cisplatin-iodized oil suspension for hepatocellular carcinoma. 2013 , 43, 1071-7		8
148	Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 703-12	6.1	72
147	Electro-coagulation for liver metastases. 2013 , CD009497		2
146	Cryotherapy for liver metastases. 2013 , CD009058		10
145	Percutaneous ethanol injection for liver metastases. 2013 , CD008717		8
144	The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. 2013 , 8, e78675		82
143	Transarterial (chemo)embolisation versus other nonsurgical ablation methods for liver metastases. 2013 ,		2
142	Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma. 2013 , 2013, 479805		18

141	Monopolar radiofrequency ablation using a dual-switching system and a separable clustered electrode: evaluation of the in vivo efficiency. 2014 , 15, 235-44	22
140	Management of Hepatocellular Carcinoma: An Update at the Start of 2014. 2014 , 04,	2
139	Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. 2014 , 35, 8451-9	21
138	Tivantinib: critical review with a focus on hepatocellular carcinoma. 2014 , 23, 1563-74	15
137	Effects of cordycepin on HepG2 and EA.hy926 cells: Potential antiproliferative, antimetastatic and anti-angiogenic effects on hepatocellular carcinoma. 2014 , 7, 1556-1562	36
136	Mexican consensus on the diagnosis and management of hepatocellular carcinoma. 2014 , 79, 250-262	
135	Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. 2014 , 2014, 203693	58
134	Mexican consensus on the diagnosis and management of hepatocellular carcinoma. 2014 , 79, 250-62	10
133	Metronomic Chemotherapy. 2014 ,	2
132	Risk factors for 1-year mortality in patients with intermediate-stage hepatocellular carcinoma treated solely with transcatheter arterial chemoembolization. 2014 , 1, 126-131	1
131	Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. 2014 , 19, 1169-78	50
130	The synergistic effect of organic silicone quaternary ammonium salt and 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo. 2014 , 23, 372-84	0
129	Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. 2014 , 37, 381-7	51
128	Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study. 2014 , 44, 523-31	51
127	Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelial-mesenchymal transition. 2014 , 18, 49-58	61
126	Magnetic resonance imaging of the liver after loco-regional and systemic therapy. 2014 , 22, 353-72	8
125	MicroRNA-122 mimic transfection contributes to apoptosis in HepG2 cells. 2015 , 12, 6918-24	8
124	The In Ovo Chick Chorioallantoic Membrane (CAM) Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma. 2015 ,	28

123	Circulating tumor cells are correlated with disease progression and treatment response in an orthotopic hepatocellular carcinoma model. 2015 , 87, 1020-8	22
122	Hepatocellular carcinoma treatment strategies in a case-based review. 2015 , 5,	2
121	Liver Cell Carcinoma in Poland: Data Reported to the National Health Fund in the Years 2008-2012. 2015 , 04,	0
120	Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultra-minimum incision personalized intratumoral chemoimmunotherapy. 2015 , 2, 57-68	1
119	Induction of apoptosis by capsaicin in hepatocellular cancer cell line SMMC-7721 is mediated through ROS generation and activation of JNK and p38 MAPK pathways. 2015 , 62, 582-91	18
118	Current and future treatments for hepatocellular carcinoma. 2015 , 21, 8478-91	112
117	Prevention of Liver Fibrosis and Cancer in Africa: The PROLIFICA project--a collaborative study of hepatitis B-related liver disease in West Africa. 2015 , 105, 185-6	3
116	Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials. 2015 , 13, 96	32
115	Stereotactic Body Radiotherapy. 2015 ,	3
114	Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. 2015 , 30, 1024-31	9
113	New Biomarkers for Early Detection of Hepatocellular Carcinoma. 2015 , 2, 370-1	1
112	Use of sensory information during postural control in children with cerebral palsy: systematic review. 2015 , 47, 291-301	24
111	A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. 2016 , 22, 7-17	199
110	Challenges of advanced hepatocellular carcinoma. 2016 , 22, 7645-59	91
109	Alpha-fetoprotein Level Predicts Recurrence After Transplantation in Hepatocellular Carcinoma. 2016 , 95, e2478	26
108	Elemeone sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1. 2016 , 6, 21010	51
107	Trace Elements and Chemotherapy Sensitivity. 2016 , 173, 283-90	5
106	Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. 2016 , 51, 1150-1160	36

105	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. 2016 , 146, 511.e1-511.e22	1
104	Effects of TMEM9 gene on cell progression in hepatocellular carcinoma by RNA interference. 2016 , 36, 299-305	11
103	Targeted nanobubbles in low-frequency ultrasound-mediated gene transfection and growth inhibition of hepatocellular carcinoma cells. 2016 , 37, 12113-12121	27
102	Targeted Therapy for Hepatocellular Carcinoma. 2016 , 26, 338-43	17
101	Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1 year experience. 2016 , 5, 1675	1
100	A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy. 2016 , 371, 205-13	25
99	[Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. 2016 , 146, 511.e1-511.e22	36
98	Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. 2016 , 51, 1011-21	27
97	Surgical Resection is Better than Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma Beyond the Milan Criteria: A Prognostic Nomogram Study. 2016 , 23, 994-1002	35
96	Management strategies for hepatocellular carcinoma: old certainties and new realities. 2016 , 16, 243-56	23
95	Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma. 2017 , 13, e304-e311	8
94	Evidence-based safety (EBS) management: A new approach to teaching the practice of safety management (SM). 2017 , 63, 21-28	35
93	TACE plus percutaneous chemotherapy-lipiodol treatment of unresectable pedunculated hepatocellular carcinoma. 2017 , 96, e7650	3
92	The antitumor activity of a lactosaminated albumin conjugate of doxorubicin in a chemically induced hepatocellular carcinoma rat model compared to sorafenib. 2017 , 49, 213-222	17
91	The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines from 2001 to 2017. 2017 , 11, 389-398	51
90	Circulating endothelial cells and risk of progression in patients with hepatocellular cancer receiving sorafenib. 2017 , 4, 39-43	2
89	Targeting Notch3 in Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Perspectives. 2016 , 18,	27
88	Systemic treatment of hepatocellular carcinoma: Past, present and future. 2017 , 9, 797-807	43

87	Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway. 2018 , 97, 1282-1288		24
86	Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. 2018 , 43, 13-25		223
85	Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ. 2018 , 43, 3-12		35
84	Chloroquine upregulates TRAIL/TRAILR2 expression and potentiates doxorubicin anti-tumor activity in thioacetamide-induced hepatocellular carcinoma model. 2018 , 279, 84-94		14
83	Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. <i>Oncotarget</i> , 2018 , 9, 4034-4043	3-3	12
82	Blood supply characteristics of pedunculated hepatocellular carcinoma prior to and following transcatheter arterial chemoembolization treatment: An angiographic demonstration. 2018 , 15, 3383-3389		1
81	Screening therapeutic targets of ribavirin in hepatocellular carcinoma. 2018 , 15, 9625-9632		6
80	Low expression of long noncoding RNA CTC-297N7.9 predicts poor prognosis in patients with hepatocellular carcinoma. 2019 , 8, 7679-7692		11
79	Sorafenib encapsulated in nanocarrier functionalized with glypican-3 specific peptide for targeted therapy of hepatocellular carcinoma. 2019 , 184, 110498		6
78	[Prevention of liver fibrosis and liver cancer linked to hepatitis B virus in Africa: the Prolifica study]. 2019 , 35, 431-439		3
77	Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines. 2019 , 20, 863-879		14
76	Five-year conditional survival for patients with hepatocellular carcinoma in Queensland, Australia. 2019 , 1, 61-69		
75	Systemic treatment of advanced hepatocellular cancer: new hope on the horizon. 2019 , 19, 343-353		8
74	MiR-204 inhibits hepatocellular cancer drug resistance and metastasis through targeting NUA1. 2019 , 97, 563-570		27
73	Implementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in Taiwan. 2019 , 11, 1013-1021		5
72	Cryotherapy for liver metastases. 2019 , 7, CD009058		5
71	Dual-task effects in children with neuromotor dysfunction: a systematic review. 2019 , 55, 281-290		7
70	Stereotactic Body Radiation Therapy: A New Strategy for Loco-Regional Treatment for Hepatocellular Carcinoma While Awaiting Liver Transplantation. 2019 , 43, 886-893		12

69	Sirolimus in Liver Transplant Recipients with Hepatocellular Carcinoma: An Updated Meta-Analysis. 2019 , 32, 632-641	13
68	Feasibility, safety, and long-term efficacy of stereotactic radiofrequency ablation for tumors adjacent to the diaphragm in the hepatic dome: a case-control study. 2020 , 30, 950-960	11
67	Circulatory miRNA as a Biomarker for Therapy Response and Disease-Free Survival in Hepatocellular Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6 6
66	Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. 2020 , 9,	9
65	Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases. 2020 , 3, CD009498	4
64	Quiescent hepatic stellate cells induce toxicity and sensitivity to doxorubicin in cancer cells through a caspase-independent cell death pathway: Central role of apoptosis-inducing factor. 2020 , 235, 6167-6182	3
63	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. 2021 , 73 Suppl 1, 158-191	63
62	Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review. 2021 , 113, 123-136	10
61	Medicare/Medicaid Insurance, Rurality, and Black Race Associated With Provision of Hepatocellular Carcinoma Treatment and Survival. 2021 , 1-9	0
60	Using Integrated Bioinformatics Analysis to Identify Abnormally Methylated Differentially Expressed Genes in Hepatocellular Carcinoma. 2021 , 14, 805-823	1
59	Interference with circRNA DOCK1 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by regulating the miR-654-5p/SMAD2 axis. 2021 , 24,	2
58	lncRNA TPT1-AS1 knockdown inhibits liver cancer cell proliferation, migration and invasion. 2021 , 24,	0
57	Electrocoagulation for liver metastases. 2021 , 1, CD009497	
56	Percutaneous ethanol injection for liver metastases.	3
55	Cryotherapy for liver metastases.	3
54	Transarterial (chemo)embolisation for liver metastases.	3
53	Chitosan nanoparticles loaded with aspirin and 5-fluororacil enable synergistic antitumour activity through the modulation of NF- κ B/COX-2 signalling pathway. 2020 , 14, 479-484	4
52	Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. 2009 , 119, 465-77	266

51	CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. 2012 , 122, 2165-75		84
50	Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial. 2013 , 8, e57397		26
49	Metronomic capecitabine versus doxorubicin in advanced hepatocellular carcinoma. 2016 , 12, 32-40		1
48	Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. <i>Oncotarget</i> , 2010 , 1, 515-529	3-3	12
47	G2/M checkpoint plays a vital role at the early stage of HCC by analysis of key pathways and genes. <i>Oncotarget</i> , 2017 , 8, 76305-76317	3-3	22
46	Novel indazole-based small compounds enhance TRAIL-induced apoptosis by inhibiting the MKK7-TIPRL interaction in hepatocellular carcinoma. <i>Oncotarget</i> , 2017 , 8, 112610-112622	3-3	6
45	A novel scoring system predicts adjuvant chemolipiodolization benefit for hepatocellular carcinoma patients after hepatectomy. <i>Oncotarget</i> , 2016 , 7, 25493-506	3-3	4
44	1, 25(OH)D ₃ inhibits hepatocellular carcinoma development through reducing secretion of inflammatory cytokines from immunocytes. 2013 , 20, 4131-41		27
43	The Effect of New Therapeutic and Diagnostic Agents on the Prognosis of Hepatocellular Carcinoma in Japan An Analysis of Data from the Kanagawa Cancer Registry. 2017 , 18, 2471-2476		5
42	Efficacy and safety of sorafenib in advanced hepatocellular carcinoma patients: a multicenter study of Kanagawa Liver Study Group. 2010 , 51, 411-417		5
41	Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. 2015 , 21, 287-94		24
40	Molecular targeting for treatment of advanced hepatocellular carcinoma. 2009 , 15, 299-308		5
39	Current approach in the treatment of hepatocellular carcinoma. 2010 , 2, 348-59		69
38	Current systemic treatment of hepatocellular carcinoma: A review of the literature. 2015 , 7, 1412-20		44
37	Treatment of hepatocellular carcinoma with portal vein thrombosis by sorafenib combined with hepatic arterial infusion chemotherapy. 2010 , 4, 423-7		12
36	Novel molecular targets in hepatocellular carcinoma. 2020 , 11, 589-605		6
35	Targeting metastatic upper gastrointestinal adenocarcinomas. 2011 , 2, 135-49		2
34	Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma. 2019 , 17, 669-675		22

- 33 A Concise Review on Current Trends in Imaging and Surgical Management of Hepatocellular Carcinoma. **2020**, 12, e9191 3
- 32 Hepatocellular Carcinoma Associated with Hepatitis B Virus. **2009**, 235-257
- 31 Molecular Targeted Therapies for HCC. **2009**, 589-614
- 30 Cancer of the Liver, Bile Duct, and Gallbladder. **2010**, 820-841
- 29 Targeted Therapies for Hepatocellular Carcinoma. **2011**, 355-368
- 28 Clinical Indications for Carbon Ion Radiotherapy and Radiation Therapy with Other Heavier Ions. **2012**, 179-192
- 27 Antiangiogenic strategies for the treatment of hepatocellular carcinoma. **2011**, 18-32
- 26 Clinical Activity of Metronomic Chemotherapy in Liver Cancers. **2014**, 189-202
- 25 Stereotactic Body Radiation Therapy to Liver. **2015**, 149-181
- 24 Contrast-Induced Nephropathy in Patients with Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization. **2016**, 06, 243-249
- 23 Elevated ZC3H15 increases HCC growth and predicts poor survival after surgical resection. *Oncotarget*, **2016**, 7, 37238-37249 3-3 6
- 22 Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. *Oncotarget*, **2017**, 8, 47555-47564 3-3
- 21 Effect of NET-1 siRNA conjugated sub-micron bubble complex combined with low-frequency ultrasound exposure in gene transfection. *Oncotarget*, **2018**, 9, 4150-4160 3-3 1
- 20 Complete Response Using Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma with Multiple Lymph Node and Bone Metastases: A Case Report. *The Showa University Journal of Medical Sciences*, **2019**, 31, 373-378 0-1
- 19 Updates in the management of hepatocellular carcinoma. *Gastroenterology and Hepatology*, **2011**, 7, 16-24 0-7 37
- 18 Cirrhosis and Chronic Viral Hepatitis as Risk Factors for Hepatocellular Carcinoma: Romanian Single-clinic Experience. *Medica*, **2010**, 5, 265-70 4
- 17 Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. *Oncotarget*, **2010**, 1, 515-29 3-3 7
- 16 The transcription factor LSF: a novel oncogene for hepatocellular carcinoma. *American Journal of Cancer Research*, **2012**, 2, 269-85 4-4 23

15	Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. <i>Current Cancer Drug Targets</i> , 2012 , 12, 1129-59	2.8	53
14	A case of necrotizing vasculitis with panniculitis, during sorafenib treatment for hepatocellular carcinoma, appeared in disease progression. <i>Journal of Gastrointestinal Oncology</i> , 2014 , 5, E121-4	2.8	2
13	MicroRNAs Related to TACE Treatment Response: A Review of the Literature from a Radiological Point of View.. <i>Diagnostics</i> , 2022 , 12,	3.8	1
12	Rap_GAP Domain of Contributes to Tumor Suppression Through mTOR Signaling in Human Hepatocellular Carcinoma.. <i>DNA and Cell Biology</i> , 2022 , 41, 215-224	3.6	
11	Risk stratification for hepatocellular carcinoma of contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) and the diagnostic performance of LR-5 and LR-M: a systematic review and meta-analysis.. <i>Clinical Radiology</i> , 2022 ,	2.9	0
10	Efficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study.. <i>Frontiers in Oncology</i> , 2021 , 11, 781029	5.3	0
9	Demystifying Lysosomal α -Fucosidase in Liver Cancer-Bearing Mice by Specific Two-Photon Fluorescence Imaging.. <i>ACS Sensors</i> , 2021 ,	9.2	0
8	Design, Synthesis, and Biological Evaluation of Novel Evodiamine Derivatives as Potential Antihepatocellular Carcinoma Agents. <i>Journal of Medicinal Chemistry</i> , 2022 , 65, 7975-7992	8.3	0
7	Prognostic MicroRNA Panel for HCV-Associated HCC: Integrating Computational Biology and Clinical Validation. <i>Cancers</i> , 2022 , 14, 3036	6.6	1
6	Sorafenib-Entrapped, Self-Assembled PullulanStearic Acid Biopolymer-Derived Drug Delivery System to PLC/PRF/5 Hepatocellular Carcinoma Model. Volume 17, 5099-5116		0
5	MicroRNAs as effective prognostic biomarkers in transarterial chemoembolization procedure for hepatocellular carcinoma patients [Correspondence. 2022 , 107, 106976		0
4	Simvastatin Induces Apoptosis And Suppresses Hepatocellular Carcinoma Induced In Rats.		0
3	Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. 2023 , 115, 102526		0
2	Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations. 2023 , 15, 2001		0
1	A Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic Therapy. 2023 , 15, 2506		0